TY - JOUR AB - Esophageal cancer is a highly aggressive and deadly disease, ranking as the sixth leading cause of cancer-related deaths worldwide. Despite advances in treatment, the prognosis remains poor. A multidisciplinary approach is crucial for achieving complete remission, with treatment options varying based on disease stage. Surgical intervention and endoscopic treatment are used for localized cancer, while systemic treatments like chemoradiotherapy and targeted drug therapy play a crucial role. Molecular markers such as HER2 and EGFR can be targeted with drugs like trastuzumab and cetuximab, and immunotherapy drugs like pembrolizumab and nivolumab show promise by targeting immune checkpoint proteins. Epigenetic modifications offer new avenues for targeted therapy. Treatment selection depends on factors like stage, tumor location, and patient health, with post-operative and rehabilitation care being essential. Early diagnosis, appropriate treatment, and supportive care are key to improving outcomes. Continued research is needed to develop effective targeted drugs with minimal side effects. This review serves as a valuable resource for clinicians and researchers dedicated to enhancing esophageal cancer treatment outcomes. AU - Acharya, R.* AU - Mahapatra, A.* AU - Verma, H.K. AU - Bhaskar, L.V.K.S.* C1 - 68907 C2 - 53761 CY - St Alban-anlage 66, Ch-4052 Basel, Switzerland SP - 9542-9568 TI - Unveiling therapeutic targets for esophageal cancer: A comprehensive review. JO - Curr. Oncol. VL - 30 IS - 11 PB - Mdpi PY - 2023 SN - 1198-0052 ER - TY - JOUR AB - Rhabdoid tumors (RT) are among the most aggressive tumors in early childhood. Overall survival remains poor, and treatment only effectively occurs at the cost of high toxicity and late adverse effects. It has been reported that the neurokinin-1 receptor/substance P complex plays an important role in cancer and proved to be a promising target. However, its role in RT has not yet been described. This study aims to determine whether the neurokinin-1 receptor is expressed in RT and whether neurokinin-1 receptor (NK1R) antagonists can serve as a novel therapeutic approach in treating RTs. By in silico analysis using the cBio Cancer Genomics Portal we found that RTs highly express neurokinin-1 receptor. We confirmed these results by RT-PCR in both tumor cell lines and in human tissue samples of various affected organs. We demonstrated a growth inhibitory and apoptotic effect of aprepitant in viability assays and flow cytometry. Furthermore, this effect proved to remain when used in combination with the cytostatic cisplatin. Western blot analysis showed an upregulation of apoptotic signaling pathways in rhabdoid tumors when treated with aprepitant. Overall, our findings suggest that NK1R may be a promising target for the treatment of RT in combination with other anti-cancer therapies and can be targeted with the NK1R antagonist aprepitant. AU - Kolorz, J.* AU - Demir, S.* AU - Gottschlich, A.* AU - Beirith, I.* AU - Ilmer, M.* AU - Lüthy, D.* AU - Walz, C.* AU - Dorostkar, M.M.* AU - Magg, T.* AU - Hauck, F.* AU - von Schweinitz, D.* AU - Kobold, S. AU - Kappler, R.* AU - Berger, M.* C1 - 63927 C2 - 51719 CY - St Alban-anlage 66, Ch-4052 Basel, Switzerland SP - 94-110 TI - The neurokinin-1 receptor is a target in pediatric rhabdoid tumors. JO - Curr. Oncol. VL - 29 IS - 1 PB - Mdpi PY - 2022 SN - 1198-0052 ER - TY - JOUR AB - Manifestation of malignant lymphoma in the spine is rare; there have only been a few cases reported in the literature. Due to its rarity, there is no gold standard for the management of patients suffering from spinal lymphoma manifestations. Methods: We retrospectively reviewed the data for 37 patients (14 female, 23 male) with malignant lymphoma in the spine receiving intervention in our center from March 2006 until June 2020. Neurological impairment, pain, diagnostics, and/or surgical instability were the criteria for surgery in this patient cohort. Otherwise, only CT-guided biopsies were conducted. Analysis of the patient cohort was based on the Karnofsky perfor-mance status scale (KPSS), location of the lesion, spinal levels involved, spinal instability neoplastic score (SINS), surgical treatment, histopathological workup, adjuvant therapy, and overall survival. The following surgical procedures were performed: posterior stabilization and decompression in nine patients; decompression and/or tumor debulking in 18 patients; a two-staged procedure with dorsal stabilization and vertebral body replacement in four patients; decompression and biopsy in one patient; a two-stage procedure with kyphoplasty and posterior stabilization for one patient; posterior stabilization without decompression for one patient; a vertebroplasty and cement-aug-mented posterior stabilization for one patient; and a CT-guided biopsy alone for two patients. Twenty-one patients (56.78%) had ≥1 lesion in the thoracic spine, 10 patients (27.03%) had lesions in the lumbar spine, two patients had lesions in the cervicothoracic junction, two patients had lesions in the thoracolumbar junction, one patient had a lesion in the lumbosacral junction, and one patient had a lesion in the sacrum. The diagnoses of the histopathological workup were diffuse large B-cell lymphoma in 23 (62.16%) cases, indolent lymphoma in 11 (29.74%) cases, anaplastic T-cell lymphoma in one case (2.70%), T-cell lymphoma in one case (2.70%), and Burkitt lymphoma in one (2.70%) case. The median overall survival was 7.2 months (range 0.1–266.7 months). Pre-and postoperative KPSS scores were 70% (IQR 60–80%). Manifestation of malignant lymphomas in the spine is rare. Similar to the approach taken for spine metastases, a surgical intervention in cases of neurological impairment or manifest or potential instability is indicated, followed by chemoimmunotherapy and radiotherapy. AU - Barz, M.* AU - Aftahy, K.* AU - Janssen, I.* AU - Ryang, Y.M.* AU - Prokop, G.* AU - Combs, S.E. AU - Jost, P.J.* AU - Meyer, B.* AU - Gempt, J.* C1 - 63335 C2 - 51478 CY - St Alban-anlage 66, Ch-4052 Basel, Switzerland SP - 3891-3899 TI - Spinal manifestation of malignant primary (Plb) and secondary bone lymphoma (slb). JO - Curr. Oncol. VL - 28 IS - 5 PB - Mdpi PY - 2021 SN - 1198-0052 ER -